Cervical squamous cell carcinoma
diseaseOn this page
Also known as cervical squamous cell cancercervix squamous cell carcinomacervix uteri squamous cell carcinomaCESCsquamous cell carcinoma of cervixsquamous cell carcinoma of cervix uterisquamous cell carcinoma of the cervixsquamous cell carcinoma of the cervix uterisquamous cell carcinoma of the uterine cervixsquamous cell carcinoma of uterine cervixsquamous cervical canceruterine cervix squamous cell carcinoma
Summary
Cervical squamous cell carcinoma (MONDO:0006143) is a cancer (an umbrella term covering 7 Mondo subtypes) with 1 cohort gene (1 CIViC-evidence somatic driver) and 56 clinical trials. Molecularly, FGFR3::TACC3 Fusion confers sensitivity to Fexagratinib in Cervical Squamous Cell Carcinoma (CIViC Level C). Top therapeutic interventions include cisplatin, topotecan, and fludeoxyglucose f 18.
At a glance
- Classification: Cancer
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Umbrella term: 7 Mondo subtypes
- Cohort genes: 1
- Clinical trials: 56
- Precision-medicine evidence (CIViC): 1 subtype–drug association
Clinical features
Epidemiology
Prevalence records
24 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 4.28 | Europe | Validated |
| Annual incidence | 1-5 / 10 000 | 11.822 | Bulgaria | Validated |
| Annual incidence | 1-5 / 10 000 | 10.336 | Estonia | Validated |
| Annual incidence | 1-5 / 10 000 | 11.192 | Lithuania | Validated |
| Annual incidence | 1-9 / 100 000 | 4.104 | Austria | Validated |
| Annual incidence | 1-9 / 100 000 | 4.67 | Belgium | Validated |
| Annual incidence | 1-9 / 100 000 | 5.539 | Croatia | Validated |
| Annual incidence | 1-9 / 100 000 | 8.277 | Czech Republic | Validated |
| Annual incidence | 1-9 / 100 000 | 1.885 | Finland | Validated |
| Annual incidence | 1-9 / 100 000 | 4.871 | Germany | Validated |
| Annual incidence | 1-9 / 100 000 | 3.707 | Iceland | Validated |
| Annual incidence | 1-9 / 100 000 | 4.204 | Ireland | Validated |
| Annual incidence | 1-9 / 100 000 | 3.307 | Italy | Validated |
| Annual incidence | 1-9 / 100 000 | 7.362 | Latvia | Validated |
| Annual incidence | 1-9 / 100 000 | 1.759 | Malta | Validated |
| Annual incidence | 1-9 / 100 000 | 4.756 | Norway | Validated |
| Annual incidence | 1-9 / 100 000 | 7.941 | Poland | Validated |
| Annual incidence | 1-9 / 100 000 | 5.478 | Portugal | Validated |
| Annual incidence | 1-9 / 100 000 | 8.555 | Slovakia | Validated |
| Annual incidence | 1-9 / 100 000 | 7.507 | Slovenia | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cervical squamous cell carcinoma |
| Mondo ID | MONDO:0006143 |
| EFO | EFO:1000172 |
| Orphanet | 213767 |
| DOID | DOID:3744 |
| ICD-11 | 1544785014 |
| NCIT | C4028 |
| SNOMED CT | 254886006 |
| UMLS | C0279671 |
| MedGen | 124644 |
| GARD | 0020487 |
| Anatomy (UBERON) | UBERON:0000002 |
| Is cancer (heuristic) | yes |
Also known as: cervical squamous cell cancer · cervical squamous cell carcinoma · cervix squamous cell carcinoma · cervix uteri squamous cell carcinoma · CESC · squamous cell carcinoma of cervix · squamous cell carcinoma of cervix uteri · squamous cell carcinoma of the cervix · squamous cell carcinoma of the cervix uteri · squamous cell carcinoma of the uterine cervix · squamous cell carcinoma of uterine cervix · squamous cervical cancer · uterine cervix squamous cell carcinoma
Data availability: 117 cell lines · 40 intOGen driver records.
Disease family
An umbrella term covering 7 Mondo subtypes.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › cervical squamous cell carcinoma
Related subtypes (38): bone squamous cell carcinoma, prostate squamous cell carcinoma, trachea squamous cell carcinoma, scrotum squamous cell carcinoma, skin squamous cell carcinoma, bladder squamous cell carcinoma, urethra squamous cell carcinoma, papillary squamous carcinoma, basaloid squamous cell carcinoma, pseudoglandular squamous cell carcinoma, thymus squamous cell carcinoma, ovarian squamous cell carcinoma, renal pelvis squamous cell carcinoma, ureter squamous cell carcinoma, fallopian tube squamous cell carcinoma, squamous carcinoma in situ, keratinizing squamous cell carcinoma, squamous cell lung carcinoma, esophageal squamous cell carcinoma, squamous cell breast carcinoma, adenosquamous carcinoma, colorectal squamous cell carcinoma, endometrial squamous cell carcinoma, gallbladder squamous cell carcinoma, gastric squamous cell carcinoma, thyroid gland squamous cell carcinoma, vaginal squamous cell carcinoma, head and neck squamous cell carcinoma, squamous cell carcinoma of the corpus uteri, squamous cell carcinoma of penis, squamous cell carcinoma of the small intestine, squamous cell carcinoma of pancreas, squamous cell carcinoma of liver and intrahepatic biliary tract, human papillomavirus-related squamous cell carcinoma, sarcomatoid squamous cell carcinoma, vulvar squamous cell carcinoma, metastatic squamous cell carcinoma, pure squamous carcinoma of the urothelial tract
Subtypes (7): cervical verrucous carcinoma, cervical basaloid carcinoma, cervical keratinizing squamous cell carcinoma, cervical lymphoepithelioma-like carcinoma, cervical non-keratinizing squamous cell carcinoma, microinvasive cervical squamous cell carcinoma, cervical adenosquamous carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Somatic driver evidence (intOGen + CIViC, cohort fanout)
| Gene | intOGen role | Cancer types | CIViC |
|---|---|---|---|
| EGFR | Act | BRCA,COADREAD,GB,GBM,HGGNOS,LGGNOS,LUAD,LUSC,NSCLC,PAST,PCM,READ,SIC | CIViC #19 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| EGFR | Orphanet:251576 | Gliosarcoma |
| EGFR | Orphanet:251579 | Giant cell glioblastoma |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| civic_only | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| EGFR | HGNC:3236 | ENSG00000146648 | P00533 | Epidermal growth factor receptor | civic_evidence |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| EGFR | Epidermal growth factor receptor | Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. |
Protein-family classification
Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Kinase | 1 | 27.7× | 0.036 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| EGFR | Kinase | yes | 2.7.10.1 | Rcpt_L-dom, Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| gingiva | 1 |
| gingival epithelium | 1 |
| nipple | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| EGFR | 285 | ubiquitous | marker | nipple, gingiva, gingival epithelium |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| EGFR | 18,421 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| EGFR | P00533 | 388 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 37. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| PLCG1 events in ERBB2 signaling | 1 | 2855.0× | 0.004 | EGFR |
| PTK6 promotes HIF1A stabilization | 1 | 1631.4× | 0.004 | EGFR |
| Inhibition of Signaling by Overexpressed EGFR | 1 | 1268.9× | 0.004 | EGFR |
| EGFR interacts with phospholipase C-gamma | 1 | 1142.0× | 0.004 | EGFR |
| EGFR Transactivation by Gastrin | 1 | 1142.0× | 0.004 | EGFR |
| ERBB2 Activates PTK6 Signaling | 1 | 815.7× | 0.004 | EGFR |
| GRB2 events in EGFR signaling | 1 | 761.3× | 0.004 | EGFR |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 1 | 761.3× | 0.004 | EGFR |
| SHC1 events in EGFR signaling | 1 | 713.8× | 0.004 | EGFR |
| Constitutive Signaling by EGFRvIII | 1 | 713.8× | 0.004 | EGFR |
| ERBB2 Regulates Cell Motility | 1 | 713.8× | 0.004 | EGFR |
| PI3K events in ERBB2 signaling | 1 | 671.8× | 0.004 | EGFR |
| Signaling by ERBB2 ECD mutants | 1 | 671.8× | 0.004 | EGFR |
| GAB1 signalosome | 1 | 634.4× | 0.004 | EGFR |
| GRB2 events in ERBB2 signaling | 1 | 634.4× | 0.004 | EGFR |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 1 | 571.0× | 0.004 | EGFR |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | 1 | 543.8× | 0.004 | EGFR |
| Signal transduction by L1 | 1 | 519.1× | 0.004 | EGFR |
| Respiratory syncytial virus (RSV) attachment and entry | 1 | 496.5× | 0.004 | EGFR |
| SHC1 events in ERBB2 signaling | 1 | 475.8× | 0.004 | EGFR |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 1 | 475.8× | 0.004 | EGFR |
| Signaling by ERBB2 TMD/JMD mutants | 1 | 475.8× | 0.004 | EGFR |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 1 | 439.2× | 0.004 | EGFR |
| Signaling by ERBB2 KD Mutants | 1 | 423.0× | 0.004 | EGFR |
| Downregulation of ERBB2 signaling | 1 | 380.7× | 0.004 | EGFR |
| Signaling by ERBB2 | 1 | 346.1× | 0.004 | EGFR |
| EGFR downregulation | 1 | 346.1× | 0.004 | EGFR |
| Signaling by EGFR | 1 | 326.3× | 0.004 | EGFR |
| Signaling by ERBB4 | 1 | 271.9× | 0.005 | EGFR |
| Extra-nuclear estrogen signaling | 1 | 170.4× | 0.007 | EGFR |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| negative regulation of cardiocyte differentiation | 1 | 16852.0× | 0.003 | EGFR |
| positive regulation of protein kinase C signaling | 1 | 5617.3× | 0.003 | EGFR |
| morphogenesis of an epithelial fold | 1 | 4213.0× | 0.003 | EGFR |
| response to UV-A | 1 | 4213.0× | 0.003 | EGFR |
| regulation of peptidyl-tyrosine phosphorylation | 1 | 3370.4× | 0.003 | EGFR |
| salivary gland morphogenesis | 1 | 2407.4× | 0.003 | EGFR |
| protein insertion into membrane | 1 | 2106.5× | 0.003 | EGFR |
| ubiquitin-dependent endocytosis | 1 | 1872.4× | 0.003 | EGFR |
| ERBB2-EGFR signaling pathway | 1 | 1685.2× | 0.003 | EGFR |
| cerebral cortex cell migration | 1 | 1532.0× | 0.003 | EGFR |
| eyelid development in camera-type eye | 1 | 1053.2× | 0.004 | EGFR |
| digestive tract morphogenesis | 1 | 991.3× | 0.004 | EGFR |
| positive regulation of phosphorylation | 1 | 842.6× | 0.004 | EGFR |
| xenobiotic transport | 1 | 842.6× | 0.004 | EGFR |
| embryonic placenta development | 1 | 766.0× | 0.004 | EGFR |
| positive regulation of peptidyl-serine phosphorylation | 1 | 766.0× | 0.004 | EGFR |
| negative regulation of epidermal growth factor receptor signaling pathway | 1 | 766.0× | 0.004 | EGFR |
| positive regulation of DNA replication | 1 | 581.1× | 0.005 | EGFR |
| positive regulation of epidermal growth factor receptor signaling pathway | 1 | 495.6× | 0.006 | EGFR |
| cellular response to estradiol stimulus | 1 | 411.0× | 0.006 | EGFR |
| positive regulation of G1/S transition of mitotic cell cycle | 1 | 401.2× | 0.006 | EGFR |
| hair follicle development | 1 | 383.0× | 0.006 | EGFR |
| negative regulation of protein catabolic process | 1 | 366.4× | 0.006 | EGFR |
| positive regulation of DNA repair | 1 | 358.6× | 0.006 | EGFR |
| cellular response to epidermal growth factor stimulus | 1 | 318.0× | 0.006 | EGFR |
| epithelial cell proliferation | 1 | 312.1× | 0.006 | EGFR |
| cellular response to amino acid stimulus | 1 | 306.4× | 0.006 | EGFR |
| positive regulation of fibroblast proliferation | 1 | 295.6× | 0.006 | EGFR |
| positive regulation of miRNA transcription | 1 | 290.6× | 0.006 | EGFR |
| positive regulation of protein phosphorylation | 1 | 276.3× | 0.006 | EGFR |
Therapeutics
Drug target analysis
Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| EGFR | LEVODOPA |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| EGFR | 175 | 4 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| LEVODOPA | 4 | EGFR |
| CLOTRIMAZOLE | 4 | EGFR |
| ERLOTINIB HYDROCHLORIDE | 4 | EGFR |
| CISPLATIN | 4 | EGFR |
| PONATINIB | 4 | EGFR |
| AFATINIB | 4 | EGFR |
| CHROMIC CHLORIDE | 4 | EGFR |
| BACITRACIN | 4 | EGFR |
| ZINC CHLORIDE | 4 | EGFR |
| LAPATINIB DITOSYLATE | 4 | EGFR |
| VEMURAFENIB | 4 | EGFR |
| FEDRATINIB | 4 | EGFR |
| AXITINIB | 4 | EGFR |
| SORAFENIB | 4 | EGFR |
| DASATINIB ANHYDROUS | 4 | EGFR |
| NICLOSAMIDE | 4 | EGFR |
| SELUMETINIB | 4 | EGFR |
| TERFENADINE | 4 | EGFR |
| ALECTINIB | 4 | EGFR |
| NERATINIB | 4 | EGFR |
| IBRUTINIB | 4 | EGFR |
| AFATINIB DIMALEATE | 4 | EGFR |
| CABOZANTINIB | 4 | EGFR |
| DACOMITINIB | 4 | EGFR |
| DACOMITINIB ANHYDROUS | 4 | EGFR |
| CERITINIB | 4 | EGFR |
| VANDETANIB | 4 | EGFR |
| TRIBROMSALAN | 4 | EGFR |
| BOSUTINIB | 4 | EGFR |
| BITHIONOL | 4 | EGFR |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| EGFR | 6,531 | Binding:6211, Functional:173, ADMET:138, Toxicity:9 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| EGFR | 2.7.10.1 | receptor protein-tyrosine kinase |
Cohort genes with high screening signal
≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.
| Symbol | ChEMBL assays |
|---|---|
| EGFR | 6,531 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Drug repurposing candidates
29 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| LEVODOPA | 4 | EGFR |
| CLOTRIMAZOLE | 4 | EGFR |
| ERLOTINIB HYDROCHLORIDE | 4 | EGFR |
| PONATINIB | 4 | EGFR |
| AFATINIB | 4 | EGFR |
| CHROMIC CHLORIDE | 4 | EGFR |
| BACITRACIN | 4 | EGFR |
| ZINC CHLORIDE | 4 | EGFR |
| LAPATINIB DITOSYLATE | 4 | EGFR |
| VEMURAFENIB | 4 | EGFR |
| FEDRATINIB | 4 | EGFR |
| AXITINIB | 4 | EGFR |
| SORAFENIB | 4 | EGFR |
| DASATINIB ANHYDROUS | 4 | EGFR |
| NICLOSAMIDE | 4 | EGFR |
| SELUMETINIB | 4 | EGFR |
| TERFENADINE | 4 | EGFR |
| ALECTINIB | 4 | EGFR |
| NERATINIB | 4 | EGFR |
| IBRUTINIB | 4 | EGFR |
| AFATINIB DIMALEATE | 4 | EGFR |
| CABOZANTINIB | 4 | EGFR |
| DACOMITINIB | 4 | EGFR |
| DACOMITINIB ANHYDROUS | 4 | EGFR |
| CERITINIB | 4 | EGFR |
| VANDETANIB | 4 | EGFR |
| TRIBROMSALAN | 4 | EGFR |
| BOSUTINIB | 4 | EGFR |
| BITHIONOL | 4 | EGFR |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 1 | EGFR |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 0 |
Undrugged target profiles
0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
Clinical trials & evidence
Clinical trials
Clinical trials: 56.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 17 |
| PHASE1 | 13 |
| PHASE3 | 9 |
| PHASE1/PHASE2 | 8 |
| Not specified | 8 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02466971 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers |
| NCT07061977 | PHASE3 | RECRUITING | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer |
| NCT00017004 | PHASE3 | COMPLETED | Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia |
| NCT00064077 | PHASE3 | COMPLETED | Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix |
| NCT00262821 | PHASE3 | TERMINATED | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer |
| NCT00803062 | PHASE3 | COMPLETED | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer |
| NCT01365156 | PHASE3 | COMPLETED | Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix |
| NCT02765919 | PHASE3 | COMPLETED | A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix |
| NCT06781073 | PHASE3 | COMPLETED | Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma |
| NCT05910827 | PHASE1/PHASE2 | RECRUITING | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers |
| NCT06543576 | PHASE1/PHASE2 | RECRUITING | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer |
| NCT06747585 | PHASE1/PHASE2 | RECRUITING | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors |
| NCT07169734 | PHASE1/PHASE2 | RECRUITING | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors |
| NCT07435376 | PHASE2 | RECRUITING | Intra-lesional Tumor Boost for Bulky Cervical Cancer |
| NCT07602842 | PHASE1/PHASE2 | NOT_YET_RECRUITING | A Study of IDP-001 in Advanced or Metastatic Solid Tumors |
| NCT00025233 | PHASE2 | COMPLETED | Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix |
| NCT00031993 | PHASE2 | COMPLETED | Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix |
| NCT00057863 | PHASE2 | COMPLETED | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer |
| NCT00217633 | PHASE2 | COMPLETED | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer |
| NCT00309959 | PHASE2 | COMPLETED | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer |
| NCT00389974 | PHASE2 | COMPLETED | Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery |
| NCT00416455 | PHASE1/PHASE2 | COMPLETED | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer |
| NCT00499031 | PHASE2 | COMPLETED | Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer |
| NCT00559377 | PHASE2 | COMPLETED | FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer |
| NCT01026792 | PHASE2 | COMPLETED | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery |
| NCT01266447 | PHASE2 | COMPLETED | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer |
| NCT01639625 | PHASE2 | COMPLETED | Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application |
| NCT01693783 | PHASE2 | COMPLETED | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer |
| NCT01807546 | PHASE2 | COMPLETED | Oral Rigosertib for Squamous Cell Carcinoma |
| NCT02042885 | PHASE1/PHASE2 | TERMINATED | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer |
| NCT02562729 | PHASE2 | COMPLETED | Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer |
| NCT02879214 | PHASE2 | UNKNOWN | Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer |
| NCT03221400 | PHASE1/PHASE2 | UNKNOWN | PEN-866 in Patients With Advanced Solid Malignancies |
| NCT03357757 | PHASE2 | COMPLETED | Avelumab With Valproic Acid in Virus-associated Cancer |
| NCT02595879 | PHASE1 | ACTIVE_NOT_RECRUITING | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer |
| NCT03983954 | PHASE1 | ACTIVE_NOT_RECRUITING | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. |
| NCT05827614 | PHASE1 | ACTIVE_NOT_RECRUITING | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications |
| NCT07217171 | PHASE1 | RECRUITING | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas |
| NCT00054444 | PHASE1 | COMPLETED | Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer |
| NCT00068549 | PHASE1 | COMPLETED | Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 14 |
| TOPOTECAN | 4 | 3 |
| FLUDEOXYGLUCOSE F 18 | 4 | 2 |
| AVELUMAB | 4 | 1 |
| EPOETIN ALFA | 4 | 1 |
| ERLOTINIB | 4 | 1 |
| FUTIBATINIB | 4 | 1 |
| GEMCITABINE HYDROCHLORIDE | 4 | 1 |
| NIRAPARIB | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| VALPROIC ACID | 4 | 1 |
| VINORELBINE TARTRATE | 4 | 1 |
| RIGOSERTIB | 3 | 2 |
| TRIAPINE | 3 | 2 |
| VELIPARIB | 3 | 2 |
| FERUMOXTRAN-10 | 3 | 1 |
| NIMOTUZUMAB | 3 | 1 |
| SPARTALIZUMAB | 3 | 1 |
| TIRAPAZAMINE | 3 | 1 |
| NAPTUMOMAB ESTAFENATOX | 2 | 1 |
| NEZUTATUG | 2 | 1 |
| WNT-974 | 2 | 1 |
| PEN-866 | 1 | 1 |
| CHEMBL3109278 | 0 | 1 |
| FOLINIC ACID | 0 | 1 |
Precision-medicine subtype map (CIViC)
Drug × molecular subtype: 1 predictive associations from 1 curated evidence items; also 1 prognostic.
| Molecular subtype | Therapy | Effect | Level | CIViC |
|---|---|---|---|---|
| FGFR3::TACC3 Fusion | Fexagratinib | Sensitivity/Response | CIViC C | EID9241 |